Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHF8 | Q9UPP1 | 4/20 | 0.40 |
| ▸ | KDM2A | Q9Y2K7 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | KDM5C | P41229 | 2/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | KDM6B | O15054 | 1/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.36 |
| ▸ | GABRP | O00591 | 3/20 | 0.35 |
| ▸ | GABRD | O14764 | 3/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21955799 | 0.78 | GLRA1 (0.39) | KDM4EGABRR1GLRA1SLC6A9OR51E2 | |
| SCHEMBL10789920 | 0.77 | CHRM2 (0.34) | — | |
| Hydrochloric Acid SCHEMBL27396677 | 0.76 | CYP1A2 (0.35) | EGLN1GABRR1CYP1A2KMT2AKDM4A | |
| SCHEMBL7747710 | 0.73 | LMNA (0.42) | PHF8KDM2AKDM4EKDM5CEGLN1 | |
| Water SCHEMBL7773339 | 0.71 | LMNA (0.40) | PHF8KDM2AKDM4EKDM5CEGLN1 | |
| SCHEMBL10644263 | 0.71 | CHRM2 (0.32) | — | |
| Hydrochloric Acid SCHEMBL8654449 | 0.71 | LMNA (0.40) | PHF8KDM2AKDM4EKDM5CEGLN1 | |
| SCHEMBL27306279 | 0.71 | ADRA2C (0.44) | PHF8KDM2AKDM4EHDAC3HDAC4 | |
| SCHEMBL4227252 | 0.71 | HDAC6 (0.40) | PHF8KDM2AKDM4EKDM5CEGLN1 | |
| SCHEMBL1521344 | 0.68 | CHRM1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108452-A1 | REGENERATIVE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | INVO Aesthetics Inc. (US) | 2026-04-23 | — | — | US | claimed |
| US-20220129965-A1 | CUSTOMIZED SKIN CARE | L Ford, Inc. | 2022-04-28 | — | — | US | claimed |
| US-11257137-B2 | Customized skin care | L Ford, Inc. (US) | 2022-02-22 | — | — | US | claimed |
| US-20190303991-A1 | CUSTOMIZED SKIN CARE | L Ford, Inc. | 2019-10-03 | — | — | US | claimed |
| US-20260108452-A1 | REGENERATIVE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | INVO Aesthetics Inc. (US) | 2026-04-23 | — | — | US | disclosed |
| US-12558302-B2 | Tyrosinase-inhibiting molecules and dermopharmaceutical composition that includes them | MESOESTETIC PHARMA GROUP, S.L (ES) | 2026-02-24 | — | — | US | disclosed |
| EP-4223740-B1 | TYROSINASE-INHIBITING MOLECULES AND DERMOPHARMACEUTICAL COMPOSITION THAT INCLUDES THEM | MESOESTETIC PHARMA GROUP S L (ES) | 2026-01-07 | — | — | EP | disclosed |
| EP-4608366-A1 | DEPIGMENTATION COMPOSITION COMPRISING L-CYSTEAMINE, ASCORBIC ACID AND PHYTIC ACID | Alphascience Research (BE) | 2025-09-03 | — | — | EP | disclosed |
| US-20240285605-A1 | DRIED COSMETIC PREPARATION FOR REHYDRATION AND USE | Onelogy Inc. (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240197601-A1 | TYROSINASE-INHIBITING MOLECULES AND DERMOPHARMACEUTICAL COMPOSITION THAT INCLUDES THEM | MESOESTETIC PHARMA GROUP S L (ES) | 2024-06-20 | — | — | US | disclosed |
| WO-2024089078-A1 | DEPIGMENTATION COMPOSITION COMPRISING L-CYSTEAMINE, ASCORBIC ACID AND PHYTIC ACID | ALPHASCIENCE RESEARCH (BE) | 2024-05-02 | — | — | WO | disclosed |
| EP-4308249-A1 | CLEANSING COMPOSITION | Li-iL GmbH Arzneimittel, Arneibäder (DE) | 2024-01-24 | — | — | EP | disclosed |
| EP-4223740-A1 | TYROSINASE-INHIBITING MOLECULES AND DERMOPHARMACEUTICAL COMPOSITION THAT INCLUDES THEM | Mesoestetic Pharma Group, S.L. (ES) | 2023-08-09 | — | — | EP | disclosed |
| CN-115175739-A | Personal care compositions | 高露洁-棕榄公司 | 2022-10-11 | — | — | CN | disclosed |
| WO-2022194928-A1 | CLEANSING COMPOSITION | LI-IL GMBH ARZNEIMITTEL, ARZNEIBÄDER (DE) | 2022-09-22 | — | — | WO | disclosed |
| EP-4059575-A1 | CLEANSING COMPOSITION | Li-iL GmbH Arzneimittel, Arneibäder (DE) | 2022-09-21 | — | — | EP | disclosed |
| US-20220129965-A1 | CUSTOMIZED SKIN CARE | L Ford, Inc. | 2022-04-28 | — | — | US | disclosed |
| US-11257137-B2 | Customized skin care | L Ford, Inc. (US) | 2022-02-22 | — | — | US | disclosed |
| CN-107997979-B | Preparation method of thermosensitive liposome with whitening effect | 苏州纳康生物科技有限公司 | 2021-02-05 | — | — | CN | disclosed |
| US-20190303991-A1 | CUSTOMIZED SKIN CARE | L Ford, Inc. | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558302-B2 | Tyrosinase-inhibiting molecules and dermopharmaceutical composition that includes them | TYR, MC1R, MITF | PHF8 869/4885KDM2A 895/4885KDM4E 1803/4885 |
| US-20260108452-A1 | REGENERATIVE COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | FGF1, FGF2, HGF | PHF8 905/4885KDM2A 3815/4885KDM4E 3811/4885 |
| US-20240197601-A1 | TYROSINASE-INHIBITING MOLECULES AND DERMOPHARMACEUTICAL COMPOSITION THAT INCLUDES THEM | TYR, MITF, MAOA | PHF8 2226/4885KDM2A 1199/4885KDM4E 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.